Thorax 1998;53:351-356 ( May )

A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment

P Pitt,^a F Li,^a P Todd,^a D Webber,^b S Pack,^b C Moniz^a

^a King's College Hospital, London, ^b Procter and Gamble Pharmaceuticals, UK

Correspondence to: Dr C Moniz, Department of Clinical Biochemistry, King's College School of Medicine and Dentistry, Bessemer Road, London SE5 9PJ, UK.

Received 8 June 1997; Returned to authors 27 August 1997; Revised version received 28 October 1997; Accepted for publication 21 November 1997

BACKGROUNDA double blind, placebo controlled study was undertaken to determine the effects of 104 weeks of intermittent cyclical etidronate therapy on bone mineral density (BMD) in patients undergoing long term oral corticosteroid therapy.
METHODSForty nine patients of mean age 59 years on long term (>6 months) corticosteroid treatment were randomised to receive either 400 mg/day etidronate or placebo for 14 days followed in both groups by calcium (equivalent to 97 mg elemental Ca/day) with vitamin D (400 IU) for 76 days. The cycle was repeated a total of eight times over a period of two years. Dual energy x ray absorptiometry (DEXA) measurements of the lumbar spine and hip BMD and biochemical bone marker analyses were performed at baseline and every six months.
RESULTSTwenty six patients (10 men) received cyclical etidronate and 23 (nine men) received placebo. The mean (SD) dose of corticosteroid (prednisone or equivalent) at baseline in the etidronate group was 8 (4) mg/day and in the placebo group was 7 (4) mg/day. Most of the patients (43%) suffered from asthma. Forty one patients completed the study (22 in the etidronate group and 19 in the placebo group). All had a low BMD at entry and with treatment a significant difference was observed between groups in the mean (SE) percentage change from baseline in lumbar spine BMD at week 104 of 4.5 (1.65)% (p = 0.007) with a 95% confidence interval (CI) of 1.12 to 7.87%. No clinically or statistically significant treatment differences were observed at the hip or with bone markers. The incidence of adverse events was similar in the two groups.
CONCLUSIONSThe results show that intermittent cyclical etidronate therapy with calcium and vitamin D supplementation significantly increases lumbar spine BMD in patients with osteoporosis resulting from long term treatment with corticosteroids.

Keywords: osteoporosis; corticosteroids; etidronate

---

© 1998 by Thorax
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Qaseem, A., Snow, V., Shekelle, P., Hopkins, R. Jr., Forciea, M. A., Owens, D. K., for the Clinical Efficacy Assessment Subcommittee, (2008). Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians. ANN INTERN MED 149: 404-415 [Abstract] [Full Text]  
• MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., Desai, S. B., Zhou, A., Chen, S., Carter, J., Tringale, C., Valentine, D., Johnsen, B., Grossman, J. (2008). Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. ANN INTERN MED 148: 197-213 [Abstract] [Full Text]  
• Gulati, S., Sharma, R. K., Gulati, K., Singh, U., Srivastava, A. (2005). Longitudinal follow-up of bone mineral density in children with nephrotic syndrome and the role of calcium and vitamin D supplements. Nephrol Dial Transplant 20: 1598-1603 [Abstract] [Full Text]  
• Licata, A. A (2005). Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates. The Annals of Pharmacotherapy 39: 668-677 [Abstract] [Full Text]  
• Campbell, I A, Douglas, J G, Francis, R M, Prescott, R J, Reid, D M (2004). Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax 59: 761-768 [Abstract] [Full Text]  
• Brown, J. P., Josse, R. G. (2003). Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada. CMAJ 168: SF1-38 [Abstract] [Full Text]  
• Brown, J. P., Josse, R. G. (2002). 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167: s1-34 [Abstract] [Full Text]  
• Biskobing, D. M. (2002). COPD and Osteoporosis. Chest 121: 609-620 [Abstract] [Full Text]  
• Yood, R. A., Harrold, L. R., Fish, L., Cernieux, J., Emani, S., Conboy, E., Gurwitz, J. H. (2001). Prevention of Glucocorticoid-Induced Osteoporosis: Experience in a Managed Care Setting. Arch Intern Med 161: 1322-1327 [Abstract] [Full Text]  
• Yosipovitch, G., Hoon, T. S., Leok, G. C. (2001). Suggested Rationale for Prevention and Treatment of Glucocorticoid-Induced Bone Loss in Dermatologic Patients. Arch Dermatol 137: 477-481 [Abstract] [Full Text]  
• Goldstein, M. F., Fallon, J. J. Jr, Harning, R. (1999). Chronic Glucocorticoid Therapy-Induced Osteoporosis in Patients With Obstructive Lung Disease*. Chest 116: 1733-1749 [Abstract] [Full Text]  
• Mitchell, D. M, Woodcock, A. (1999). Introduction. Thorax 54: S1-1  
• COWAN, S., MORIN, S., ERNST, P. (1998). Bisphosphonates and glucocorticoid-induced osteoporosis: implications for patients with respiratory diseases. Thorax 53: 331-332 [Full Text]  
• SOCIETY, B. T., COMMITTEE, S. O. C. (1990). The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults---British Thoracic Society recommendations. Thorax 54: 1S-28 [Full Text]